Weekly Roundup: Insulet Jumps, Disney Surges, Palantir Disappoints

On this episode of Stock Movers:

- Insulet (PODD) shares rallied this week, soaring up as much as 20% during trading on an upbeat earnings report. The insulin delivery system maker boosted its revenue guidance for the full year and posted better-than-expected first-quarter results. Piper Sandler views the guidance increase positively and as more evidence of strong momentum in the business.

- Disney (DIS) shares rose after it reported fiscal second-quarter results that beat Wall Street estimates and raised its outlook for the full year, citing strong performances from theme parks and streaming TV. Full-year 2025 earnings, excluding certain items, will rise 16% to $5.75 a share, Disney said Wednesday in a statement, about double its previous forecast for growth. Analysts were looking for $5.44 a share. A number of major companies have pulled their 2025 guidance amid the uncertainty caused by US President Donald Trump’s tariffs on imported goods. But Disney is benefiting from faster-than-expected growth at its namesake parks and streaming business, and pointed to that strong performance to boost its guidance.

- Palantir (PLTR) shares slid by the most in nearly a year after its financial results and projections failed to live up to investors’ lofty expectations. The company described rising demand for artificial intelligence software as a “ravenous whirlwind” and bumped its 2025 revenue forecast on Monday to about $3.9 billion from about $3.75 billion. But even a solid earnings results beat and the raised outlook wasn’t enough to justify the stock’s high valuation and extend its massive year-to-date gain. Palantir’s shares tanked by as much as 14.9% to $105.32, the lowest intraday price since May 7, 2024. The stock was still up 41% for the year.

See omnystudio.com/listener for privacy information.